Introducing Color’s formal collaborations with NCI-Designated Cancer Centers for access and speed.

Learn more
PublishedNovember 18, 2026

The Zip Code Problem in Cancer: What Poor Access Costs Employers

Rebecca Miksad, MD, MPH
Chief Medical Officer

Poor access in rural populations across the United States can contribute to higher cancer costs through clinical challenges: delayed diagnostic appointments that take months to secure, treatment decisions made without necessary test results, limited clinical trial options, and symptoms that worsen between visits to distant clinics. Limited access is more than an inconvenience; multiple studies show worse outcomes for patients with cancer outside of metropolitan areas.

The Business Group on Health’s 2027 survey found that 70% of surveyed employers named cancer the top condition driving healthcare spending; 92% percent ranked it among their top three. For employers with rural workforces, these cancer care delivery gaps must also be addressed for health benefits to remain sustainable.

A cancer benefit on paper does not guarantee the same care in practice. Understanding that difference starts with knowing what patients need, and what happens when they do not receive it.


Same disease, different odds

Geography is associated with the chance of surviving cancer. Five years after diagnosis, fewer patients with cancer in nonmetropolitan areas were alive compared to patients with the same stage of cancer in metropolitan areas, according to a 2025 American Cancer Society study. Lower survival generally aligned with lower receipt of cancer treatment in this assessment.

A separate study of more than 3.6 million patients with lung, prostate, breast, and colorectal cancer diagnosed from 1975 to 2011 documented a similar rural survival lag, after adjusting for sociodemographic and clinical factors. Survival improved in both groups over the decades, but the rural gap persisted, particularly for breast cancer. Rural populations also have modestly higher overall cancer incidence, including early-onset colorectal cancer. These findings are sobering: even as survival has improved for everyone, a rural gap has persisted.


Impact of rural cancer specialist gap

Although definitions of “rural” vary and county-based designations may include both small towns and open countryside, the key commonality is distance from cancer specialists, who tend to be located in more urban areas. In 2025, 68.5% of U.S. counties, home to about 50.8 million people (roughly 15% of the population), had no radiation oncology practice site. Nearly 17% of U.S. adults older than 35 would have to drive more than 100 miles to reach an NCI-funded site, locations where clinical trial enrollment is often highest. For patients, the distance has practical consequences and imposes barriers to care.

An appointment for cancer care means time away from work, coverage for child and elder care, transportation costs, and sometimes an overnight stay. Cancer diagnosis, treatment and follow-up typically require frequent appointments: daily for radiation, weekly for chemotherapy, as well as every couple of months after the end of treatment for a common surveillance plan. Additional appointments are needed for labs, imaging, specialist assessments, and management of side effects.

And, appointments are frequent. For example, a study published this year commercially insured women aged 18–64 with non-metastatic breast cancer who had surgery as their first treatment averaged 54.4 outpatient visits (SD, 24.6) in the first year, including radiation sessions and therapy appointments. The average ranged from 47.1 to 57.7 visits by treatment type. In a similar study of commercially insured patients with metastatic pancreatic cancer, the mean number of outpatient visits was 6.6 per month (SD 3.4), with a median of 6 (IQR 4.4–8.1).

These findings raise a clinical question: how to best maintain access to the expertise patients need despite geographic limitations? For employers, the answer also identifies where avoidable costs begin.


The decisions behind the costs

Cancer care is a long series of complex decisions, from initial testing and cancer diagnosis, to treatment, symptom management, and survivorship. Proximity to expertise matters so that new results, treatment response, and side effects appropriately inform next steps.

When access is limited, each decision point becomes harder to address promptly and optimally. Five recurring clinical care gaps illustrate how clinical problems become expensive claims:

  1. Late diagnosis of a screenable or preventable cancer. Limited access to screening and follow-up appointments can delay cancer diagnosis, missing the opportunity to diagnose (and treat) cancers when they are more likely to be curable.

  2. Insufficient diagnostic workup. Delayed or inaccessible staging, biomarker, and other tests can hinder timely and personalized treatment decisions.

  3. Sub-optimal treatment plan. The cancer treatment landscape is rapidly evolving and often requires multi-disciplinary input. Subspecialist expertise matters when the diagnosis is complex or several treatment options exist.

  4. Unmanaged symptoms. Delayed assessment and intervention risk complications, treatment interruptions, and the need for emergency care.

  5. Expensive treatment delivered in higher cost settings. Comprehensive clinical review includes both the treatment plan and the treatment setting to ensure safety and to accommodate the patient’s needs.

These care delivery gaps affect all patients with cancer. However, rural patients are more likely to face limited options when a test, specialist appointment, or clinical assessment is needed.


What the access gap could cost your plan

A “back of the envelope” calculation illustrates why these gaps deserve employers’ attention. Consider an employer with 40% of its workforce residing in rural communities and the following realistic assumptions:

The combination of high rates of later stage disease and their higher treatment costs would mean the average cancer treatment cost is roughly 3–11% higher for a rural employee. When spread across the full population, this translates to 1.4–4.4% higher cancer treatment costs. If annual cancer care spending totaled $10 million with the urban stage distribution applied to everyone, the difference adds roughly $140,000 – $440,000 a year in cancer treatment cost.

This example estimates only the impact of a later stage at diagnosis, which may be due to many different factors including higher incidence of some cancers and care delivery barriers. Other costs that may be higher in non-urban settings include incomplete workups, sub-optimal treatment, unmanaged symptoms, and lost workdays. Actual costs depend on the employer’s population and claims experience.


Why a benefit alone does not close the gap

Current benefits approaches can fall short when they don’t change the care model.

A center of excellence offers specialized expertise. For a patient who lives hours away, repeated travel remains a barrier throughout their treatment journey.

A second opinion provides a review at a particular point in care. Patients also need clinical decisions before and after the review because results, symptoms, and treatment response can change recommendations.

A referral identifies where a patient needs to go. It takes clinical outreach to communicate urgency when local capacity is limited. Administrative case management does not replace a clinician who assesses symptoms, orders tests, or changes medications.

These needs continue after treatment. A cancer survivor typically needs monitoring for recurrence, management of long-term side effects, and evaluation of new symptoms. The nearest clinician with experience in that cancer may still be hours away.

For employers, the question is whether the benefit changes what happens at these points in care. Coverage matters, and patients need a practical way to use it.


What the evidence tells us

Nonetheless, geography is not destiny; a study of 36,995 patients with cancer enrolled in clinical trials from 1982 to 2012 found no difference in outcomes by rural vs urban location in 16 of 17 disease groups. While clinical trial eligibility introduces its own bias towards healthier patients who can travel to a trial site, it is notable that delivering standardized treatment under comparable conditions yielded similar outcomes regardless of where the participant lived.

The way we deliver care deserves attention alongside the treatments themselves.


Bringing expertise into patients’ lives

Color built its Virtual Cancer Clinic around clinical management and oversight from early detection through active treatment and survivorship. Its oncologist-led medical group operates across all 50 states, with 24/7 clinical access and collaboration with local treating physicians.

The clinical purpose is straightforward: make expertise available when a decision needs attention.

Every patient with a confirmed cancer diagnosis receives proactive, continuous Expert Medical Opinion in collaboration with their treating physicians. Reviews address the diagnosis, diagnostic workup, treatment plan, facility, clinical trial options, and symptom management.

Color repeats that review at key decision points throughout care. In our internal analysis the team identified at least one care recommendation for 95% of patients.

That recommendation is the start of the clinical work. The next step is to address it with the patient and treating physician, then reassess when circumstances change.

One Color patient took a virtual visit from the cab of his tractor because harvest left no other time. Color completed his cancer risk assessment, arranged a colonoscopy, and managed follow-up through completion. Another patient spoke with Color about symptom management every Monday morning on his commute to work because it was the only time he had privacy.

The visit setting matters throughout the cancer journey because it makes a clinical conversation possible within the context of the patient’s life. Patients need a way to raise concerns, receive an assessment, and act on symptoms without waiting for their next scheduled specialist visit. The care model connects with the care that follows so that in-person care is focussed on where it is needed.


Expert cancer care, wherever employees live

Rural and urban employees do not need identical care pathways. They need identical access to timely expertise.

For patients, that means a diagnostic workup that informs treatment, a plan reviewed whenever decisions need to be made, and symptoms that receive clinical attention. For employers, those same decisions address the gaps behind avoidable high-cost claims.

Color brings that expertise to employees and collaborates with their local treating physicians throughout care in a way that can reduce total cancer cost of care by 25–30%.

Geography remains part of patients’ lives. The way we deliver cancer care needs to account for it.

References

  1. Islami F, Wiese D, Schafer EJ, Sung H, Jemal A. Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021. Cancer. 2025;131(19):e70073. doi:10.1002/cncr.70073

  2. Lewis-Thames MW, Langston ME, Khan S, et al. Racial and ethnic differences in rural-urban trends in 5-year survival of patients with lung, prostate, breast, and colorectal cancers: 1975-2011 Surveillance, Epidemiology, and End Results (SEER). JAMA Netw Open. 2022;5(5):e2212246. doi:10.1001/jamanetworkopen.2022.12246

  3. Business Group on Health. 2027 Employer Healthcare Strategy Survey: Full Report. August 25, 2026. Accessed November 16, 2026. https://www.businessgrouphealth.org/resources/2027-employer-healthcare-strategy-survey-full-report

  4. Semprini J, Gadag K, Williams G, Muldrow AQ, Zahnd WE. Rural-urban cancer incidence and trends in the United States, 2000 to 2019. Cancer Epidemiol Biomarkers Prev. 2024;33(8):1012-1022. doi:10.1158/1055-9965.EPI-24-0072

  5. Yu C, Lu SG, Arons D, Rowley JP, Sindhu KK. Structural vulnerability in the United States radiation oncology delivery system: predictors and consequences of practice site disappearance. Int J Radiat Oncol Biol Phys. Published online July 9, 2026. doi:10.1016/j.ijrobp.2026.06.3090

  6. Shriver SP, Sahar L, Douangchai Wills VL, Adams DV, Fleury ME. Assessing populations with access to National Cancer Institute-funded sites using local distance-based service areas. J Clin Transl Sci. 2025;9:e218. doi:10.1017/cts.2025.10148

  7. Proussaloglou EM, Ren Y, Fayanju OM, et al. Patient out-of-pocket costs and healthcare utilization related to mastectomy vs breast conservation: a claims-based study. J Surg Oncol. 2026;134(2):185-196. doi:10.1002/jso.70281

  8. Fuldeore R, Amaefule AQ, Georgieva G, Kimura T, Jiang B, Yu KH. Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis. Future Oncol. 2026;22(15):1803-1813. doi:10.1080/14796694.2026.2682510

  9. National Grange; Xcenda. Cancer disproportionately impacts adults living in rural areas: unmet need for cancer screening tests is greatest in rural areas. Issue brief. 2023. Accessed November 10, 2026. https://edge.growthzonecms.com/sites/2383/2025/09/Cancer_disparities_issue_brief.pdf

  10. Oh DL, Wang K, Goldberg D, et al. Disparities in cancer stage of diagnosis by rurality in California, 2015-2019. Cancer Epidemiol Biomarkers Prev. 2024;33(11):1523-1531. doi:10.1158/1055-9965.EPI-24-0564

  11. Sherr HR, Soliman AS, Bertrand KA, Hirko KA. Persistent poverty and late-stage breast cancer diagnosis in the United States: impacts of rural residence, race, and time within Surveillance, Epidemiology, and End Results registries, 2004 to 2021. Cancer Causes Control. 2025;36(11):1589-1597. doi:10.1007/s10552-025-02043-x

  12. Sepassi A, Li M, Zell JA, Chan A, Saunders IM, Mukamel DB. Rural-urban disparities in colorectal cancer screening, diagnosis, treatment, and survivorship care: a systematic review and meta-analysis. Oncologist. 2024;29(4):e431-e446. doi:10.1093/oncolo/oyad347

  13. Reddy SR, Broder MS, Chang E, Paydar C, Chung KC, Kansal AR. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. doi:10.1080/03007995.2022.2047536

  14. Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23-32. doi 10.1007/s40274-018-5525-7

  15. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Canc Netw. 2018;16(4):402-410. doi:10.6004/jnccn.2017.7065

  16. Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open. 2018;1(4):e181235. doi:10.1001/jamanetworkopen.2018.1235